Show simple item record

dc.contributor.authorLee, Janice Soo Fern*
dc.contributor.authorCalmy, Alexandra*
dc.contributor.authorAndrieux-Meyer, Isabelle*
dc.contributor.authorFord, Nathan*
dc.date.accessioned2012-04-24T17:45:05Z
dc.date.available2012-04-24T17:45:05Z
dc.date.issued2012-01-11
dc.identifier.citationHIV AIDS Res Palliat Care 2012; 12(4):5-15en
dc.identifier.issn1179-1373
dc.identifier.pmid22347806
dc.identifier.doi10.2147/HIV.S20993
dc.identifier.urihttp://hdl.handle.net/10144/220338
dc.description.abstractIntegrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug-drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.
dc.language.isoenen
dc.publisherDovePressen
dc.relation.urlhttp://www.dovepress.com/review-of-the-safety-efficacy-and-pharmacokinetics-of-elvitegravir-wit-peer-reviewed-article-HIVen
dc.rightsArchived with thanks to HIV/AIDS (Auckland, N.Z.)en
dc.subject.meshAcquired Immunodeficiency Syndromeen
dc.subject.meshAntiviral Agentsen
dc.titleReview of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settingsen
dc.typeArticleen
dc.contributor.department1Médecins Sans Frontières; HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africaen
dc.identifier.journalHIV/AIDS - Research and Palliative Careen
refterms.dateFOA2019-03-04T09:43:20Z
html.description.abstractIntegrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug-drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.


Files in this item

Thumbnail
Name:
120111_Lee_Review-of-the-safet ...
Size:
189.6Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record